Across 53 CTIS-indexed Phase II–III psoriasis and psoriatic arthritis trials, Phase III accounts for 40 trials, or 75.5% of the cohort. The operational footprint is strongly weighted toward Poland, Germany, Spain, Italy, Czechia, Hungary, and Romania, with Poland showing the highest summed country-level participant allocation and the densest recurrent site network.
The cohort includes 53 trials: 40 Phase III trials and 13 Phase II trials. Phase III therefore represents 75.5% of the analyzed trial set, while Phase II represents 24.5%.
This is a late-stage-heavy market. Site capacity is therefore less about exploratory proof-of-concept access and more about repeatable, multi-country enrollment networks able to support confirmatory dermatology and rheumatology programs.
The top 10 recurring sites appear across 3–6 trial-country records each. Poland contributes the largest number of recurrent private clinical research networks, while Germany, Spain, Hungary, and Czechia contribute both university hospitals and specialized outpatient research centers.
| Rank | Site | Country | Trial records |
|---|---|---|---|
| 1 | Medicover Integrated Clinical Services Sp. z o.o. | Poland | 6 |
| 2 | Hospital Germans Trias I Pujol | Spain | 4 |
| 3 | Charite Universitaetsmedizin Berlin KöR | Germany | 4 |
| 4 | L.K.N. Arthrocentrum s.r.o. | Czechia | 4 |
| 5 | Futuremeds network | Poland / Spain | 4 |
| 6 | University Of Debrecen | Hungary | 4 |
| 7 | Centrum Kliniczno-Badawcze J. Brzezicki B. Gornikiewicz-Brzezicka | Poland | 4 |
| 8 | Dermed Centrum Medyczne Sp. z o.o. | Poland | 3 |
| 9 | Hospital De La Santa Creu I Sant Pau | Spain | 3 |
| 10 | Semmelweis University | Hungary | 3 |
The leading site list is not dominated only by major academic hospitals. Specialized private research centers and outpatient rheumatology/dermatology networks appear repeatedly, which suggests that operationally scalable community-based sites are central to psoriasis and psoriatic arthritis enrollment.
Across summed country-level allocations, Poland ranks first with 1,793 participants, followed by Germany with 1,245 and Spain with 895. The top 5 countries account for 5,273 participants across the analyzed country records.
The country pattern points to a Central and Eastern European enrollment engine, especially Poland, Czechia, Hungary, Romania, and Bulgaria, combined with Western European academic access in Germany, Spain, Italy, France, and Belgium.
Psoriasis-focused records account for 31 of 53 trials, or 58.5%. Psoriatic arthritis or mixed psoriatic arthritis/rheumatology records account for 22 of 53 trials, or 41.5%. Phase II is more arthritis-weighted, while Phase III is more plaque psoriasis-weighted.
The operational site network has two overlapping but distinct layers: dermatology-heavy plaque psoriasis programs and rheumatology-heavy psoriatic arthritis programs. Countries with both dermatology and rheumatology site depth are therefore more strategically useful for portfolio-level planning.